Pfizer (NYSE:PFE) Stock Rating Reaffirmed by Cantor Fitzgerald

Pfizer (NYSE:PFE)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued on Wednesday, Benzinga reports. They presently have a $45.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 61.87% from the company’s current price.

PFE has been the subject of several other reports. Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Price Performance

PFE stock opened at $27.80 on Wednesday. The firm has a 50 day moving average of $27.81 and a 200-day moving average of $27.69. Pfizer has a 12-month low of $25.20 and a 12-month high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The company has a market cap of $157.53 billion, a price-to-earnings ratio of -458.26, a PEG ratio of 1.10 and a beta of 0.70.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the previous year, the firm posted $1.23 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, equities analysts expect that Pfizer will post 2.38 EPS for the current fiscal year.

Institutional Trading of Pfizer

Several institutional investors have recently made changes to their positions in PFE. Clifford Swan Investment Counsel LLC lifted its position in shares of Pfizer by 4.7% during the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after purchasing an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $255,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $16,166,000. Finally, KLCM Advisors Inc. boosted its holdings in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after purchasing an additional 74,487 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.